3.5-Di-tert-butyl-4-hydroxybenzaldehyd | 145176-77-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3.5-Di-tert-butyl-4-hydroxybenzaldehyd
• 英文别名: 3,5-Dibutyl-4-hydroxybenzaldehyde
• CAS: 145176-77-8
• 化学式: C₁₅H₂₂O₂
• 分子量: 234.338
• InChiKey: UPRBDTIUGNMSMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3.5-Di-tert-butyl-4-hydroxybenzaldehyd 、 氰乙酰胺 在 哌啶 作用下， 以 乙醇 为溶剂， 以66%的产率得到(E)-2-Cyano-3-(3,5-dibutyl-4-hydroxy-phenyl)-acrylamide
  参考文献：
  名称：

  Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors

  摘要：

  A novel class of low molecular weight protein tyrosine kinase inhibitors is described. These compounds constitute a systematic series of molecules with a progressive increase in affinity toward the substrate site of the EGF receptor kinase domain. These competitive inhibitors also effectively block the EGF-dependent autophosphorylation of the receptor. The potent EGF receptor kinase blockers examined were found to competitively inhibit the homologous insulin receptor kinase at 10(2)-10(3) higher inhibitor concentrations in spite of the significant homology between these protein tyrosine kinases. These results demonstrate the ability to synthesize selective tyrosine kinase inhibitors. The most potent EGF receptor kinase inhibitors also inhibit the EGF-dependent proliferation of A431/clone 15 cells with little or no effect on EGF independent cell growth. These results demonstrate the potential use of protein tyrosine kinase inhibitors as selective antiproliferative agents for proliferative diseases caused by the hyperactivity of protein tyrosine kinases. We have suggested the name "tyrphostins" for this class of antiproliferative compounds which act as protein tyrosine kinase blockers.

  DOI：

  10.1021/jm00130a020

文献信息

• [EN] ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS<br/>[FR] COMPOSÉS D'ARYLOXYAMINE ET LEUR UTILISATION COMME MODULATEURS DES CANAUX SODIQUES
  申请人：HOWARD FLOREY INST

  公开号：WO2009055869A1

  公开（公告）日：2009-05-07

  The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In one embodiment the invention is concerned with the treatment of neuropathic pain. The invention contemplates to aryloxy-substituted amines, as sodium channel blockers or modulators. In further embodiments, the invention also relates to compounds which may advantageously have dual sodium channel blocker/modulating and antioxidative (free-radical scavenging) effects. Methods for their manufacture and compositions containing the compounds are also contemplated.

  本发明通常涉及治疗和具有相关用途的化合物领域，特别是与通过细胞膜的电压门控钠通道传递过多、不需要或不希望的钠离子相关的病症的治疗或管理。在一个实施例中，该发明涉及神经病性疼痛的治疗。该发明考虑到芳基氧基取代胺，作为钠通道阻滞剂或调节剂。在进一步的实施例中，该发明还涉及可能具有双重钠通道阻滞/调节和抗氧化（自由基清除）效果的化合物。还考虑了其制造方法和含有这些化合物的组合物。